Previous 10 | Next 10 |
The rising stock market had many winners on Wednesday, but alas for its shareholders FibroGen (NASDAQ: FGEN) wasn't one of them. The biotech's shares declined by over 9% following a downgrade from a famous investment bank. Goldman Sachs analyst Paul Choi has downshifted his ...
Earnings news and analyst comments provided key themes for midday trading on Wednesday. Stitch Fix (NASDAQ:SFIX) was one of the standout gainers on the session, posting a double-digit advance after releasing strong financial figures. Turning to analyst comments, SoFi Technologies (NASDAQ:SOFI...
SAN FRANCISCO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive topline results from WHITNEY, the Company’s Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PH...
Last month, the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the U.S. Food and Drug Administration (FDA) denied AstraZeneca (NASDAQ: AZN) and FibroGen 's (NASDAQ: FGEN) drug roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD)....
TOKYO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that the European Commission (EC) has approved EVRENZO™ ...
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor availa...
SAN FRANCISCO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. Pat will continue as Chief Financial Officer through September 6, 2021, and will remain with Fib...
SAN FRANCISCO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney di...
Image source: The Motley Fool. FibroGen, inc (NASDAQ: FGEN) Q2 2021 Earnings Call Aug 9, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: FibroGen, inc (FGEN) Q2 2021 Earnings Call Transcript
FibroGen, Inc. (FGEN) Q2 2021 Results Conference Call August 9, 2021 5:00 PM ET Company Participants Michael Tung - Vice President of Corporate Strategy and Investor Relations Enrique Conterno - Chief Executive Officer Pat Cotroneo - Chief Financial Officer Mark Eisner - Chief Medical Officer...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...